1. Corteva partnership scale-up - GRANUVIA and Spinoace, launched with Corteva in May-July 2026, generated \~₹5.3 cr in Q1 FY27, with a combined FY27 expectation of ₹30-35 cr gross, \~₹25 cr net. Two more Corteva products are slated for launch, extending a partnership that has already moved from a single product to a portfolio.
2. Sotanala greenfield plant - The \~₹200 cr Sotanala facility starts formulations around April-May 2027 and technical production by Diwali 2027, with \~₹70 cr already invested. This adds new active-ingredient capacity and headroom beyond the current Chopanki and Dahej plants.
3. Dahej expansion and backward integration - Over 70% of the Dahej facility is commercialized, with the new L&T-built technical plant manufacturing just started and expected profitable post-Diwali. The expansion consolidates capacity for 8-9 new active ingredients and moves production to n-4/n-5 basic stages, improving margins.
4. New product pipeline - More than 30 products are in the pipeline for launch over the next 2 years, with 2 launched in Q1 FY27 contributing ₹5.50 cr in the quarter. Revenue from products launched last year grew from ₹23 cr to ₹82 cr, showing the earnings step-up from fresh launches.
5. Kaeros B2B and brand build-out - Kaeros, acquired for under ₹6 cr, reached \~₹110 cr FY26 revenue with a PAT margin above ₹5 cr, and targets at least doubling total sales in FY27 as the Dr. Dada brand launches. Direct China imports and pack-to-pack business for fertilizer companies add a new B2B channel.
6. Premiumisation mix shift - Maharatna and Focus Maharatna products reached 64% of B2C contribution in Q1 FY27, up from 58% a year earlier, against a 70% target in 3-4 years. Premium products carry 35%+ gross margins versus generics, so the mix shift lifts overall profitability.
7. OAT Agrio discovery molecule - The first discovery product from the OAT JV is expected in 2027, with the data pack ready to file once the IUPAC name clears and the first Indian patent filing expected this year. A patented molecule can cross 50% margins versus the 35% average, and the JV's profit share is already rising.
8. Export and CDMO ramp - Exports, currently \~5% of revenue, target 10% in 2-3 years, backed by 180+ registrations across 22 countries and initial CDMO trial supplies going out. Latin America business has started small, with next year the deciding year for scale.